- Home
- ORC vs REPL Comparison
ORC vs REPL Comparison
Compare ORC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- REPL
- Stock Information
- Founded
- ORC 2010
- REPL 2015
- Country
- ORC United States
- REPL United States
- Employees
- ORC N/A
- REPL N/A
- Industry
- ORC Real Estate Investment Trusts
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- ORC Real Estate
- REPL Health Care
- Exchange
- ORC Nasdaq
- REPL Nasdaq
- Market Cap
- ORC 660.1M
- REPL 757.8M
- IPO Year
- ORC 2013
- REPL 2018
- Fundamental
- Price
- ORC $7.03
- REPL $12.13
- Analyst Decision
- ORC Hold
- REPL Strong Buy
- Analyst Count
- ORC 3
- REPL 7
- Target Price
- ORC N/A
- REPL $20.83
- AVG Volume (30 Days)
- ORC 3.8M
- REPL 1.5M
- Earning Date
- ORC 07-24-2025
- REPL 08-07-2025
- Dividend Yield
- ORC 20.51%
- REPL N/A
- EPS Growth
- ORC N/A
- REPL N/A
- EPS
- ORC 0.46
- REPL N/A
- Revenue
- ORC $52,240,000.00
- REPL N/A
- Revenue This Year
- ORC $46.17
- REPL N/A
- Revenue Next Year
- ORC $26.45
- REPL N/A
- P/E Ratio
- ORC $15.31
- REPL N/A
- Revenue Growth
- ORC N/A
- REPL N/A
- 52 Week Low
- ORC $5.69
- REPL $6.44
- 52 Week High
- ORC $9.01
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- ORC 46.51
- REPL 69.61
- Support Level
- ORC $7.10
- REPL $9.26
- Resistance Level
- ORC $7.28
- REPL $9.90
- Average True Range (ATR)
- ORC 0.11
- REPL 0.57
- MACD
- ORC -0.00
- REPL 0.19
- Stochastic Oscillator
- ORC 32.89
- REPL 88.68
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.